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Abstract (239 words) 38 
Rapid and accurate drug-susceptibility testing (DST) is essential for the treatment of multi- 39 
and extensively drug-resistant tuberculosis (M/XDR-TB). We compared the utility of 40 
genotypic DST assays with phenotypic DST (pDST) using BACTEC 960 MGIT or 41 
Löwenstein-Jensen to construct M/XDR-TB treatment regimens for a cohort of 25 42 
consecutive M/XDR-TB patients and 15 possible anti-TB drugs. 43 
Genotypic DST results from Cepheid GeneXpert MTB/RIF (Xpert) and line probe assays 44 
(LPAs: Hain GenoType MTBDRplus 2.0 and MTBDRsl 2.0)] and whole genome sequencing 45 
(WGS) were translated into individual algorithm-derived treatment regimens for each patient. 46 
We further analysed if discrepancies between the various methods were due to flaws in the 47 
genotypic or phenotypic test using MIC results. 48 
Compared with pDST, the average agreement in the number of drugs prescribed in 49 
‘genotypic’ regimens ranged from just 49% (95% CI 39-59%) for Xpert and 63% (95% CI 50 
56-70%) for LPAs to 93% (95% CI 88-98%) for WGS. Only the WGS regimens did not 51 
comprise any drugs to which pDST showed resistance. Importantly, MIC testing revealed that 52 
pDST likely underestimated the true rate of resistance for key drugs (rifampicin, levofloxacin, 53 
moxifloxacin, and kanamycin) because critical concentrations (CCs) were too high. 54 
WGS can be used to rule-in resistance even in M/XDR strains with complex resistance 55 
patterns, but pDST for some drugs is still needed to confirm susceptibility and construct the 56 
final regimens. Some CCs for pDST need to be re-examined to avoid systematic false-57 
susceptible results in low-level resistant isolates.  58 
 o
n
 January 18, 2018 by London School of Hygiene & Tropical M
edicine
http://aac.asm
.org/
D
ow
nloaded from
 
 
 
INTRODUCTION 59 
Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide (1). Although the 60 
global incidence of TB has been slowly declining, the emergence of multidrug-resistant 61 
(MDR)-TB, defined as resistance to rifampicin and isoniazid, challenges TB-control (1). 62 
Extensively drug-resistant (XDR)-TB, defined as MDR-TB and resistance to at least one 63 
fluoroquinolone [e.g. ofloxacin, levofloxacin, or moxifloxacin; World Health Organization 64 
(WHO) group A] and any second-line injectable drug (SLID, amikacin, kanamycin, or 65 
capreomycin; WHO group B) has been reported in 117 countries (1). 66 
 67 
Therapy of M/XDR-TB is complex and requires a long duration of treatment with a 68 
combination of at least four drugs often leading to adverse-events and poor treatment 69 
outcomes (2, 3). Moreover, the initiation of appropriate therapy is often delayed due to the 70 
slow growth rate of Mycobacterium tuberculosis complex isolates, which means that 71 
phenotypic drug-susceptibility testing (pDST) can take weeks to months (4, 5). To accelerate 72 
this rate-limiting step, a number of genotypic DST assays that detect resistance mutations 73 
have been endorsed by the WHO (6). The Cepheid GeneXpert (Xpert) is an automated point-74 
of-care assay with a high diagnostic accuracy for rifampicin-resistance detection, providing 75 
results within 1.5 hours (7). Line probe assays (LPAs, e.g. Hain GenoType MTBDRplus 2.0 76 
and MTBDRsl 2.0) can also be performed directly from sputum to provide results within 1-2 77 
days with a high diagnostic accuracy for resistance to isoniazid, rifampicin, fluoroquinolones, 78 
and SLIDs (6). Because these assays only target a limited number of resistance variants, their 79 
sensitivity compared with pDST is limited. Whole genome sequencing (WGS) can 80 
theoretically overcome this shortcoming by interrogating the entire genetic repertoire (4, 5, 8). 81 
Nevertheless, the utility of WGS is currently limited by the need for expensive equipment, 82 
highly trained personnel, and complex bioinformatic procedures. Moreover, WGS requires an 83 
initial culture, which introduces a delay compared with the aforementioned targeted assays (6, 84 
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9). More fundamentally, there is a lack of understanding of the genetic basis of antibiotic 85 
resistance, which complicates the interpretation of WGS data (10). 86 
 87 
However, it is important to appreciate that discrepancies observed between pDST and 88 
genotypic methods are not exclusively due to problems related to the interpretation of the 89 
genotype (6). Instead, the evidence is mounting that some critical concentrations (CCs), which 90 
are set by the Clinical and Laboratory Standards Institute (CLSI) and/or WHO and define 91 
resistance on a phenotypic level, are higher than the epidemiological cut-off values 92 
(ECOFFs), which represent the highest concentration of the wild-type MIC distribution (6, 93 
11-15). As a result, some isolates with elevated MICs compared to the ECOFF due to known 94 
mutations are classified as susceptible even though limited 95 
pharmacokinetic/pharmacodynamics or clinical outcome data evidence exists that these 96 
isolates are still treatable (6, 12, 13, 16). 97 
 98 
Therefore, this study had two main goals. First, we compared the utility of genotypic methods 99 
(Xpert, LPAs, and WGS) with pDST to design M/XDR regimens using standardised 100 
algorithms. Second, we analysed whether discrepancies between the various methods were 101 
due to flaws in pDST or the genotype.  102 
 o
n
 January 18, 2018 by London School of Hygiene & Tropical M
edicine
http://aac.asm
.org/
D
ow
nloaded from
 
 
 
RESULTS 103 
Patient cohort 104 
20 patients with MDR-TB and 5 with XDR-TB admitted to the Medical Clinic of the 105 
Research Center Borstel (Germany) were enrolled (Table S1). 106 
 107 
Comparison of M/XDR TB regimens based on pDST with molecular methods 108 
367 pDST results for a total of 15 drugs served as the reference standard (Figure 1). Xpert 109 
classified all 25 patients as having rifampicin resistance, yet one isolate was phenotypically 110 
susceptible, resulting in an agreement of 96% (95% CI 80-100%). LPA and pDST results 111 
agreed in 228 of 243 cases [94% (95% CI 90-97%)]. 340 of the 367 WGS-based drug 112 
resistance predictions [93% (95% CI 89-95%)] were concordant with pDST (Figure 1A, Table 113 
S2). 114 
 115 
There was a 49% (95% CI 39-59%) average agreement in number of antibiotics prescribed 116 
between the regimens based on Xpert results alone and those based on pDST (Figure 2 and 117 
Table S3) (3). This increased to 68% (95% CI 56-80%), if resistance to both ethambutol and 118 
pyrazinamide was also assumed based on the discovery of rifampicin resistance. Making the 119 
equivalent assumption for LPAs increased the agreement from 63% (95% CI 56-70%) to 87% 120 
(95% CI 80-94%). The best agreement with pDST regimens was achieved with WGS [93% 121 
(95% CI 88-98%)] (Figure 2 and Table S3). Importantly, the WGS regimens did not feature 122 
any drugs to which resistance was found using pDST. In contrast, the 25 regimens that were 123 
designed using LPAs or the Xpert contained 56/152 [37% (95% CI 29-56)] and 77/150 [51% 124 
(95% CI 43-60%)] drugs respectively, for which pDST showed resistance (Table S4). 125 
 126 
A more detailed analysis of drug categories revealed that the Xpert regimens involved an 127 
increased administration of group A, B, and D1 drugs compared with pDST (P<0.001) (Table 128 
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S5). Moreover, no D2 and D3 drugs were part of these regimens (P<0.001). For the LPA 129 
regimens, only the increase in the number of D1 drugs was statistically significant. By 130 
contrast, the use of WGS resulted in a significant decrease in the use of D1 drugs because 131 
more ethambutol resistance was predicted (Table S5). 132 
 133 
Analysis of the discrepancies between different DST methods 134 
We determined the MICs for selected isolates and antibiotics to investigate the potential 135 
causes of the discrepancies observed with the different DST methods (Table S2). 136 
 137 
Rifampicin and rifabutin 138 
One isolate (11102-14) with an rpoB D435Y mutation had an MIC for rifampicin that was 139 
below the CC, but above the tentative ECOFF defined in this study (tentative ECOFF=0.25 140 
μg/ml < rpoB mutant=0.5 μg/ml < CC=1 μg/ml), which suggested that the susceptible pDST 141 
result likely represented a breakpoint artefact (Figure 3A). This isolate also tested susceptible 142 
to rifabutin at the CC of 0.5 μg/ml (Figure 3B). In this case, however, the result was likely 143 
valid as its MIC (0.06 μg/ml) was even lower than the tentative ECOFF (0.12 μg/ml). By 144 
contrast, the susceptible pDST results to rifabutin for the D435Y and L452P/E481A isolates 145 
(12041-13 and 999-13) were again likely the result of a breakpoint artefacts (17). 146 
 147 
Isoniazid and prothionamide 148 
All gWT isolates tested susceptible at the CLSI and WHO CC of 0.1 μg/ml. Conversely, all 149 
isolates with elevated MICs had known resistance mutations. Although not endorsed by WHO 150 
and not considered for our hypothetical regimens, CLSI has set 0.4 μg/ml as an additional 151 
breakpoint to define low-level resistance that can be treated with a high dose of isoniazid 152 
according to some recommendations (Figure 3C) (18). Based on our WGS results, we were 153 
able to predict that all gNWT isolates were resistant even at this higher concentration [either 154 
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because of the katG S315T mutation, which is known to confer predominantly high-level 155 
resistance, or because the isolates harboured both the inhA -15c/t promoter mutation and inhA 156 
coding changes (S94A or I194T) (18, 19)]. It was not possible to predict the correct level of 157 
resistance for the inhA double mutants using the MTBDRplus given that this assay only 158 
interrogates promoter mutations (20). 159 
 160 
For prothionamide, we only observed a single disagreement between our WGS predictions 161 
and pDST (21). Isolate 3758-14 originally tested susceptible despite a frameshift mutation in 162 
ethA (22). However, this discrepancy was likely a random error since the isolate was found to 163 
have an elevated MIC compared with the CC (>25 μg/ml vs. 2.5 μg/ml, respectively). 164 
 165 
Levofloxacin and moxifloxacin 166 
All seven isolates with known gyrA resistance mutations were resistant to levofloxacin at the 167 
CC of 1.5 μg/ml (23). However, a review of MIC data from the literature revealed a tentative 168 
ECOFF of 0.75 μg/ml, which resulted in the misclassification of 9 gyrA isolates from the 169 
literature (Figure 4A). 170 
 171 
WHO has set two CCs for moxifloxacin. The lower CC at 0.5 μg/ml is supposed to 172 
correspond to the ECOFF and is intended as a surrogate for ofloxacin and levofloxacin 173 
resistance (14, 24). However, our pooled MIC data suggested that the tentative ECOFF was 174 
actually 0.25 μg/ml, which was in agreement with the current CLSI guidelines (Figure 4B) 175 
(11). All of our gyrA mutants were resistant at 2 μg/ml, the second WHO CC, which should 176 
define resistance to moxifloxacin itself (i.e. isolates with only slightly elevated MICs of 1 and 177 
2 μg/ml are deemed to still be treatable with moxifloxacin). However, in light of the fact that 178 
WHO has already acknowledged that this CC may be too high and given that predicting the 179 
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precise MIC based on genotypic data alone is challenging, we simply classified our isolates as 180 
gNWT (24). 181 
 182 
SLIDs 183 
The MIC distribution for isolates with known mutations in the resistance genes eis and whiB7 184 
ranged from 2.5 to 10-12.5 μg/ml and was truncated by the current CC of 2.5 μg/ml, whereas 185 
all gWT isolates had MICs ≤0.125 μg/ml (25-27). Therefore, the two isolates with an MIC of 186 
2.5 μg/ml (12471-13 and 11411-14) would have tested resistant if the CC was lowered to the 187 
tentative ECOFF of 1.25 μg/ml (Figure 5A and Table S2). Moreover, we would predict isolate 188 
811-15, which had a known whiB7 resistance mutation (-56 g/a), to retest resistant at 1.25 189 
μg/ml (it tested susceptible at 2.5 μg/ml and no MIC data were available for this isolate) (26). 190 
Two isolates had a previously unknown deletion of the upstream and coding region of eis, 191 
which resulted in an invalid result with the MTBDRsl assay. The effect of this change on 192 
kanamycin resistance remains to be determined. 193 
 194 
No discrepancies were observed for amikacin and capreomycin (28). 195 
 196 
Other antibiotics 197 
No discrepancies were found for streptomycin and pyrazinamide (29-33). For linezolid, 198 
isolate 9685-14 had a novel 23S mutation (rrl 906 g/a) that was observed in a susceptible 199 
isolate. 200 
 201 
For the remaining antibiotics, we found evidence of false-susceptible pDST results. In the 202 
case of ethambutol, all 25 isolates were classified as gNWT but four tested susceptible (34-203 
36). Up to five isolates, as opposed to two just phenotypically confirmed isolates, might have 204 
been cycloserine resistant given that the recently proposed tentative ECOFF of 20 μg/ml is 205 
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below the CC of 30 μg/ml (37). Finally, up to six additional isolates could have been resistant 206 
to para-aminosalicylic acid based on the WGS data (see supplementary results).  207 
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DISCUSSION 208 
We investigated how different genotypic DST assays influence the design of standardised 209 
algorithm-derived M/XDR-TB regimens. As expected, the accuracy of predicting resistance 210 
and, consequently, the ability to design appropriate treatment regimen correlated with the 211 
proportion of the genome analysed. Moreover, we demonstrated that the pDST results were 212 
flawed in some cases. 213 
  214 
Although LPAs have been endorsed by the WHO for the rapid molecular prediction of drug-215 
resistance of rifampicin, isoniazid, fluoroquinolones, and SLIDs, the Xpert is the most 216 
frequently used assay for initial routine molecular DST in many high-burden countries (6). 217 
Based on our results, it is a good test to rule-in rifampicin resistant TB that can be used as 218 
surrogate marker for M/XDR-TB depending on the geographical region. However, it is 219 
paramount that these results are complemented with additional DST since a treatment 220 
regimens based only on an Xpert result would have led to the ineffective administration of 221 
approximately half of the drugs in this cohort of patients who were predominantly from 222 
Eastern Europe. This will be different in other geographic settings, where the extent of drug 223 
resistance beyond rifampicin and isoniazid is lower (38, 39). 224 
 225 
The prediction of resistance to fluoroquinolones and SLIDs by LPAs was generally accurate 226 
for patients in this cohort. However, this test was also insufficient to construct appropriate 227 
M/XDR-TB regimens compared with pDST, especially in patients with XDR-TB. For 228 
example, almost all of the patients with M/XDR-TB from this cohort had strains that were 229 
resistant to ethambutol and pyrazinamide, which are not covered by the MTBDRsl 2.0. This 230 
was in line with results from a European study at 26 different centres in high-intermediate- 231 
and low-burden countries of TB that reported resistance to pyrazinamide and ethambutol in 232 
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59.7% and 59.3% of all patients with MDR-TB (94.4% and 81.8% of patients with XDR-TB), 233 
respectively (38, 39). 234 
 235 
The M/XDR-TB treatment regimens based on WGS showed the highest agreement [93% 236 
(95% CI 88-98%)] with those based on pDST. Unlike the other genotypic assays, WGS did 237 
not miss any phenotypically confirmed resistances, but did predict resistance in some 238 
phenotypically susceptible isolates. This was partly due to the fact that we identified novel or 239 
poorly defined mutations that we could not interpret with regard to their impact on resistance 240 
development (e.g. mutations in rrl or gyrB; Table S2). Here, we adopted a conservative 241 
approach and assumed that these mutations conferred resistance, until disproved by another 242 
method, e.g. MIC determination of mutants derived from allelic exchange experiments and 243 
sequential patient derived isolates that allow the interpretation of individual mutations and 244 
their effect on the drug resistance level in a particular phylogenetic strain background. 245 
 246 
In other cases, problems with pDST played a role. The false-susceptible pDST results for 247 
ethambutol were likely due to the fact that some resistance mutations only result in slight MIC 248 
increases, which means that it can be difficult to distinguish the gWT strains from gNWT 249 
strains using pDST, unless secondary mutations increase the MICs even further (14, 40-42). 250 
The lack of reproducibility of pDST was also apparent for isolate 3758-14, which initially 251 
tested susceptible to prothionamide but became resistant upon retesting (Table S2). 252 
 253 
Our results highlighted breakpoint artefacts (i.e. cases in which the current CCs were likely 254 
set above the tentative ECOFFs) as a major cause for systematic errors. In the absence of 255 
well-documented, high-quality evidence that isolates with elevated MICs can be treated with 256 
the standard or an elevated dose, the CCs for these drugs should be lowered to the tentative 257 
ECOFFs to avoid misdiagnosing isolates with elevated MICs as susceptible (12, 13). One 258 
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possibility to gather such evidence would be to conduct a placebo-controlled study in which 259 
high-dose rifampicin or rifabutin is used to treat low-level rpoB resistance mutations as part 260 
of a backbone M/XDR-TB regimen (43). 261 
 262 
Importantly, we raised the possibility that breakpoint artefacts may exist for six drugs that 263 
constitute the backbone of the treatment of drug-susceptible TB or MDR TB (i.e. rifampicin, 264 
levofloxacin, moxifloxacin, and kanamycin) in addition to less widely used drugs (i.e. 265 
rifabutin and cycloserine). The impact of this phenomenon depends on the geographic setting. 266 
For example, low-level resistance mutations in rpoB account for more than 10% of rifampicin 267 
resistance in Bangladesh, but are less frequent in other countries (44, 45). Problems related to 268 
kanamycin pDST are likely to be important in Eastern Europe where eis mutations are 269 
widespread amongst the dominant MDR TB clones (46, 47). 270 
 271 
This study was limited given that it was retrospective and only featured a small number of 272 
MDR and XDR patients from a single centre although the comparison between genotypic 273 
DST and pDST was strengthen by inclusion of MIC determinations of fully susceptible 274 
isolates from Sweden (n=15). Our results did not provide direct evidence that treatment 275 
regimen based on different genotypic DST methods have an impact on clinical outcomes. 276 
Moreover, data from more laboratories including both drug resistant and drug susceptible 277 
isolates are required to set ECOFFs with confidence (16, 48). Nevertheless, the fact that 278 
potential breakpoint artefacts were found for so many key drugs underlines the urgent need 279 
for both CLSI and WHO to re-examine their CCs, which were largely set based on expert 280 
opinion using evidence that was not or insufficiently documented, as opposed to modern and 281 
transparent principles pioneered by the European Committee on Antimicrobial Susceptibility 282 
Testing (EUCAST) (6, 12, 16). Importantly, this should include clear recommendations about 283 
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how to proceed when discrepant results between genotypic assays and pDST are found (49). 284 
Ideally, these recommendations should consider MICs as well as clinical outcome data. 285 
 286 
In conclusion, the strength of this study was that instead of merely calculating the 287 
concordance of genotypic DST results compared with pDST, as is customary for these 288 
assessments, we also compared the resulting regimens. In our view, this is more clinically 289 
meaningful as TB is never treated with a single drug (in effect, we assessed the situation in 290 
settings that lack the laboratory infrastructure for pDST or, alternatively, the period whilst 291 
pDST is being carried out but its results are not yet available). This is an important distinction 292 
since the concordance of a genotypic DST assay with pDST can be deceptively high [96% 293 
(95% CI 80-100%) for Xpert in our case], yet more than half of the drugs in the resulting 294 
regimens would still be prescribed inappropriately. Xpert and LPA results should therefore 295 
only be used to rule-in resistance to WHO group A/B drugs and need to be complemented 296 
with further testing. WGS can provide important additional information on resistance to WHO 297 
group C/D drugs but cannot replace pDST completely either (e.g. pDST is still needed for 298 
novel mutations and to detect resistance caused by known resistance mutations that occur at 299 
frequencies below the detection limit of WGS (6)). Finally, the CCs need to be re-evaluated to 300 
avoid systematic false susceptible pDST results for a variety of first and second line drugs.  301 
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MATERIALS AND METHODS 302 
Study population 303 
All patients (n=25) with a diagnosis of M/XDR-TB admitted to the Medical Clinic of the 304 
Research Center Borstel (Germany) between March 2013 and March 2015 were included 305 
consecutively in the study. 306 
 307 
Microbiology, pDST and MIC testing 308 
The primary detection, enrichment, DST, and MIC testing for the Germany isolates were done 309 
under routine conditions at the German National Reference Laboratory for Mycobacteria, 310 
Borstel. The following CCs in μg/ml were used for pDST with the BACTEC 960 MGIT 311 
system using a critical proportion of 1% for all drugs, with the exception of pyrazinamide, for 312 
which 10% was employed: rifampicin (1.0), rifabutin (0.5), isoniazid (0.1), prothionamide 313 
(2.5), ofloxacin (2.0), levofloxacin (1.5), moxifloxacin (0.5 & 2.0), kanamycin (2.5), amikacin 314 
(1.0), capreomycin (2.5), para-aminosalicylic acid (4.0), streptomycin (1.0), ethambutol (5.0), 315 
pyrazinamide (100.0), and linezolid (1.0) (11, 14). Cycloserine was tested using the 316 
proportion method on Löwenstein-Jensen medium using a CC of 30 μg/ml and a critical 317 
proportion of 1% (14). 318 
 319 
The following concentrations in μg/ml were included for MGIT MIC testing for clinical 320 
isolates: rifampicin (0.12, 0.25, 0.5, 1.0, 4.0, 20.0), rifabutin (0.06, 0.12, 0.25, 0.5, 2.0, 10.0), 321 
isoniazid (0.1, 0.4, 1.0, 3.0, 10.0), prothionamide (0.62, 1.25, 2.5, 5.0, 10.0, 25.0), 322 
levofloxacin (0.18, 0.37, 0.75, 1.5), moxifloxacin (0.06, 0.12, 0.25, 0.5), kanamycin (0.31, 323 
0.62, 1.25, 2.5, 5.0, 12.5, 25.0), amikacin (0.12, 0.25, 0.5, 1.0, 4.0, 20.0, 40.0), capreomycin 324 
(0.31, 0.62, 1.25, 2.5, 5.0, 12.5, 25.0), and para-aminosalicylic acid (0.5, 1.0, 2.0, 4.0). The 325 
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following concentrations ranges in μg/ml were tested in two-fold dilutions for the M. 326 
tuberculosis H37Rv ATCC 27294 reference strain: rifampicin (0.06-0.5), rifabutin (0.06-0.5), 327 
isoniazid (0.006-0.05), prothionamide (0.31-2.5), levofloxacin (0.09-1.5), moxifloxacin (0.06-328 
0.5), kanamycin (0.31-2.5), amikacin (0.12-1), capreomycin (0.31-2.5), para-aminosalicylic 329 
acid (0.5-4), and linezolid (0.12-1). 330 
 331 
Molecular DSTs 332 
All baseline sputum specimens were analysed with the Xpert assay according to the 333 
recommendation of the manufacturer. Genomic DNA extracted with cetyltrimethylammonium 334 
bromide from Löwenstein-Jensen cultures was used for the MTBDRplus 2.0 and MTBDRsl 335 
2.0 LPAs as well as for WGS using a modified Illumina NexteraXT protocol and the MiSeq 336 
or NextSeq sequencers (20, 50-52). The detection of a inhA promotor variant with the 337 
MTBDRplus was used to infer prothionamide resistance (18). The raw data (fastq files) was 338 
submitted to the European Nucleotide Archive (Table S2). Resulting reads were aligned to the 339 
M. tuberculosis H37Rv genome (GenBank ID: NC_000962.3) using BWA-MEM (53). The 340 
GATK software package was utilized for base quality re-calibration and alignment correction 341 
for possible PCR or insertion/deletion artefacts (54). Polymorphisms with a minimum of 10x 342 
coverage and 75% variant frequency were extracted and combined for all isolates using 343 
customized perl scripts. We focused our analysis on 33 resistance genes (Table S6), for which 344 
known polymorphisms that do not correlate with resistance (i.e. phylogenetic variants) were 345 
excluded (Table S7) (5, 55, 56). 346 
 347 
WGS data were analysed as follows (15). Isolates that did not have any mutations or only 348 
harboured neutral polymorphisms in drug-resistance genes (Table S7) were classified as 349 
genotypically wild-type and were assumed to be susceptible (gWT-S). Isolates with mutations 350 
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known to result in MICs above the current CC that defines resistance [i.e. MICs > CC(R)] 351 
were classified as genotypically non-wild-type and resistant (gNWT-R). Where two CCs have 352 
been set to define intermediate resistance (i.e. isolates that are treatable with an elevated dose 353 
of the drug), isolates with mutations that result in MICs within this range [i.e. CC(S) < MIC ≤ 354 
CC(R)] were gNWT intermediate (gNWT-I). gNWT susceptible (gNWT-S) was used to refer 355 
to isolates with mutations that confer elevated MICs below the lowest CC [i.e. ECOFF < MIC 356 
≤ CC(S)]. Isolates with likely or known resistance mutations that do not necessarily result in 357 
MICs above the CC(S/R) (i.e. in the case of ethambutol and kanamycin) or that confer MIC 358 
increases above the CC(S) but not necessarily above the CC(R) were classified as simply 359 
gNWT. Mutations with no or insufficient evidence with regards to their effect on MICs were 360 
classified as ‘unclear’. 361 
 362 
Algorithm-derived treatment regimens  363 
We retrospectively designed treatment regimens based on the results obtained from each DST 364 
method (pDST, Xpert, LPAs, and WGS) using current MDR-TB treatment recommendations, 365 
as outlined in the supplementary methods (3). To err on the side of caution, unclear and 366 
gNWT mutations from WGS were considered to be resistant. The 367 initial pDST results 367 
served as reference standard for all comparisons (15 drugs for 25 patients with eight missing 368 
results, which could not be conducted because of biosafety concerns). 369 
 370 
Statistics  371 
Concordance between each diagnostic test result with phenotypic DST was scored for every 372 
individual on a scale from 0 to 1 with 0 representing no concordance and 1 perfect 373 
concordance for each individual test result. The same approach was used to assess the overlap 374 
between the different treatment regimens for each individual regimen. Differences in scores 375 
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were evaluated using the Mann Whitney U test. The overlap between different diagnostic 376 
methods and the agreement between the different treatment regimens were evaluated using 377 
the differences in proportions where each drug from a given group was considered 378 
independently. Graphs were created and statistics calculated using STATA version 14 379 
(STATA Corp., Texas, USA) and Prism Version 5 (Pad Software Inc., La Jolla, California, 380 
USA). P-values below 0.05 were considered as significant. 381 
  382 
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Determining tentative ECOFFs 383 
We set tentative ECOFFs by visual inspection for a variety of antibiotics (statistical methods 384 
could not be used given the MIC data did not meet the minimum requirements specified by 385 
EUCAST to set ECOFFs (48)). For this purpose, we pooled the MICs from the German 386 
patient cohort with MICs from a Swedish collection (see supplementary methods) and the 387 
literature, wherever the individual concentrations and concentration ranges were sufficiently 388 
similar (17, 19, 27, 57, 58). As shown in Table S8, we had to truncate some of the 389 
distributions for this purpose. For Kambli et al. we excluded one isolate, for which the genetic 390 
basis of the elevated MICs was not clear (27). We did not display the MICs for gyrB 391 
mutations from Nosova et al. given the mutations differed from the gyrB A504V mutation 392 
observed in our study (57). We only included MIC data for rpoB mutations from Berrada et 393 
al. that also occurred in the German isolates (17). 394 
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Figure legends 662 
Figure 1: Comparison of pDST, Xpert, LPA, and WGS results and corresponding 663 
regimens 664 
Upper panels: Results for pDST and molecular methods (Xpert, LPAs, and WGS) for 25 M. 665 
tuberculosis isolates from patients with M/XDR-TB. Test results denoting either confirmed 666 
phenotypic susceptibility or assumed susceptibility based on genotypic methods are shown in 667 
green, those denoting resistance are in red, gNWT variants with elevated MICs are in orange, 668 
whereas mutations with unclear effects are in grey. Differences between Xpert, LPA, or WGS 669 
results compared to the pDST are outlined by black margins (both gNWT and unclear variants 670 
were assumed to be resistant for the purposes of designing the regimens and results between 671 
DST methods). 672 
Lower Panels: Standard algorithm-derived treatment regimens based on respective results of 673 
pDST, LPAs, WGS, and Xpert. Differences of resulting therapy regimens in comparison to 674 
the pDST-derived treatments are highlighted by black boxes. Vertical bars indicate data for 15 675 
drugs for each patient, i.e. from left to right isoniazid (H), rifampicin (R), rifabutin (Rb), 676 
ethambutol (E), pyrazinamide (Z), kanamycin (Km), amikacin (Am), capreomycin (Cm), 677 
ofloxacin (Ox), moxifloxacin (Mx), levofloxacin (Lx), prothionamide (Pt), para-678 
aminosalicylic acid (Pa), cycloserine (Cs), terizidone (Tz), amoxicillin/clavulanic acid (Ac), 679 
Meroprenem (Me), clofazimine (Cf), delamanid (De), bedaquiline (Bq) 680 
 681 
Figure 2: Average overlap of different regimens based on molecular DST assays 682 
compared with pDST results. 683 
Standard algorithm-derived treatment regimens based on results of Xpert, LPAs, and WGS 684 
(X-axis) with their mean overlap to standard algorithm-derived treatment regimens based on 685 
pDST results (Y-axis). Mean overlaps (dots) are expressed with 95% confidence intervals 686 
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(bars). P values assessing the differences between the mean overlaps between the treatment 687 
regimens are shown above.  688 
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Figure 3: MIC distributions for rifampicin, rifabutin and isoniazid 689 
A+B) The CCs for rifampicin and rifabutin were two dilutions higher than the tentative 690 
ECOFFs defined based on the pooled MIC data from this study and the literature (i.e. 1 vs. 691 
0.25 μg/ml for rifampicin and 0.5 vs. 0.12 μg/ml for rifabutin) (17). These distinctions did not 692 
make a difference for isolates with rpoB S450F or S450L mutations, which resulted in large 693 
MIC increases for both drugs. By contrast, the susceptible resistance result to rifampicin by 694 
pDST for the rpoB D435Y isolate (11102-14), as well as the rifabutin results for the rpoB 695 
D435V and L452P/E481A isolates (12041-13 and 999-13) likely were breakpoints artefacts, 696 
as the isolates had elevated MIC levels compared with gWT isolates and the H37Rv 697 
laboratory strain. By contrast, the rpoB D435Y isolate appeared to be genuinely susceptible to 698 
rifabutin. However, lowering the CCs for both drugs to the ECOFFs would not necessarily 699 
ensure that isolates with elevated MICs always test resistant phenotypically. For example, 700 
because the MIC distribution of rpoB D435V (0.12-0.5 μg/ml) overlapped with the gWT 701 
distribution of rifabutin, the normal variation in MIC testing would result in a poor 702 
reproducibility of pDST for this mutation. 703 
 704 
C) WHO has only endorsed a single critical concentration for isoniazid, whereas CLSI has set 705 
an additional breakpoint that defines high-level resistance. Some treatment guidelines 706 
recommend the treatment of low-level resistant strains with a high dose of isoniazid (18). All 707 
mutant isolates were found to be resistant even at the second CLSI breakpoint, which was in 708 
accordance with our prediction based on WGS data (18). This would not have been apparent 709 
using the GenoType MTBDRplus assay given that it only interrogates inhA promoter 710 
mutations, which typically result in low MICs, although this did not affect our interpretation 711 
of the assay since we only relied on the WHO CC (18).  712 
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Figure 4: MIC distributions for levofloxacin and moxifloxacin 713 
The pooled MIC data identified potential breakpoint artefacts for both agents. First, the CLSI 714 
and WHO critical concentrations for levofloxacin were one dilution higher than the tentative 715 
ECOFF defined in this study (1.5 vs 0.75 μg/ml) (11, 14). Second, the pooled data supported 716 
the current CLSI critical concentration (0.25 μg/ml) as the tentative ECOFF for moxifloxacin 717 
rather than the value set by WHO (0.5 μg/ml), which is designed as a surrogate for testing 718 
resistance to ofloxacin and levofloxacin (24). Moreover, WHO has acknowledged that the 719 
critical concentration at 2 μg/ml that defines resistance to moxifloxacin may be too high (24). 720 
Because two isolates with different genetic backgrounds shared the same gyrB A504V 721 
mutations, which is typically a signal of positive selection, these isolates were categorized as 722 
unclear. However, MIC testing revealed MICs that were equal or below even the tentative 723 
ECOFFs for both fluoroquinolones, which was in line with allelic exchange experiments (59). 724 
 725 
Figure 5: MIC distributions for kanamycin, amikacin and capreomycin 726 
The direct alteration of rrs, the shared target of kanamycin, amikacin, and capreomycin, via 727 
the A1401G mutation is known to confer unequivocal cross-resistance to all three drugs, 728 
which was in agreement with the pooled MIC data (60). By contrast, the current CCs for 729 
kanamycin was found to truncate the MIC distribution for isolates with eis and whiB7 730 
mutations (27). This meant that isolates with an MIC of 2.5 μg/ml were misclassified as 731 
susceptible despite the fact these included mutations that had been shown to result in elevated 732 
MICs using allelic exchange experiments (i.e. eis -37 g/t, eis -10 g/a and whiB7 -116 a/g) (25, 733 
26). By contrast, neither eis nor whiB7 mutations had a significant impact on the MICs of 734 
amikacin or capreomycin (based on previous data, the fact that the tentative ECOFF for 735 
capreomycin for our study was below the critical concentration was likely an artefact due to 736 
the small number of gWT isolates included in this study) (61). 737 
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